Introduction: Several clinical trials comparing the efficacy and safety of transarterial
chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no …

Objective This trial compared the efficacy and safety of transarterial chemoembolisation
(TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint …

Purpose To compare the time to progression (TTP) and overall survival (OS) in patients with
advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment …

Background Sorafenib is used in patients with intermediate or advanced stage
hepatocellular carcinoma (HCC) before or after of transarterial chemoembolization (TACE) …

The multikinase inhibitor sorafenib is the first oral molecular targeted agent with proven
prognostic benefit in unresectable advanced hepatocellular carcinoma (HCC). However, as …

Objective This prospective non‐randomized controlled trial aimed to compare the efficacy of
sorafenib in combination with transarterial chemoembolization (TACE) vs TACE alone for …

Background & Aims Sorafenib is first-line standard of care for patients with advanced
hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed …

Background Hepatocellular carcinoma (HCC) is the most common liver neoplasm and the
fifth most common cancer worldwide. Intermediate stage HCC [traditionally defined as …

This phase II, investigator‐initiated, prospective single‐arm multinational study
(ClinicalTrials. gov registration NCT00990860) evaluated sorafenib in combination with …

Background Transarterial chemoembolisation (TACE) is the standard of care for patients
with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib …